Cost-effectiveness of sentinel lymph node biopsy in thin melanomas
- 1 October 2003
- Vol. 134 (4), 542-547
- https://doi.org/10.1016/s0039-6060(03)00275-7
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Tumour thickness as a predictor of occult lymph node metastases in patients with stage I and II melanoma undergoing sentinel lymph node biopsyBritish Journal of Surgery, 2002
- Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging SystemJournal of Clinical Oncology, 2001
- Final Version of the American Joint Committee on Cancer Staging System for Cutaneous MelanomaJournal of Clinical Oncology, 2001
- Melanoma thickness and histology predict sentinel lymph node statusThe American Journal of Surgery, 2001
- Thin #1 mm Level III and IV Melanomas Are Higher Risk Lesions For Regional Failure and Warrant Sentinel Lymph Node BiopsyAnnals of Surgical Oncology, 2000
- Role for Lymphatic Mapping and Sentinel Lymph Node Biopsy in Patients With Thick (?4 mm) Primary MelanomaAnnals of Surgical Oncology, 2000
- Validation of the Accuracy of Intraoperative Lymphatic Mapping and Sentinel Lymphadenectomy for Early-Stage MelanomaAnnals of Surgery, 1999
- Multi-Institutional Melanoma Lymphatic Mapping Experience: The Prognostic Value of Sentinel Lymph Node Status in 612 Stage I or II Melanoma PatientsJournal of Clinical Oncology, 1999
- Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.Journal of Clinical Oncology, 1996
- A subset in which Level Is the Major Prognostic IndicatorAnnals of Surgery, 1985